Finerenone (Kerendia): The Kidney-and-Heart Drug for Diabetes

TL;DR: Finerenone, sold as Kerendia, is a newer drug that protects the kidneys and heart by blocking the mineralocorticoid (aldosterone) receptor, which drives inflammation and scarring when overactive. In people with type 2 diabetes and chronic kidney disease, it slowed kidney disease and lowered cardiovascular events on top of standard care, and in 2024 a trial extended its benefit to a hard-to-treat form of heart failure, leading to FDA approval for that use in 2025. In 2026, the FIND-CKD trial extended its kidney benefit to people who have chronic kidney disease without diabetes, though it is not yet FDA-approved for that group. It is a nonsteroidal cousin of spironolactone with far fewer hormonal side effects, but its defining risk is high potassium, so potassium and kidney function are monitored. It is a targeted add-on for specific higher-risk patients, often alongside an SGLT2 inhibitor, rather than a longevity drug for the general public.

What is finerenone, and how is it different from older drugs like spironolactone?

Finerenone, sold as Kerendia, blocks a receptor in the body called the mineralocorticoid receptor, which responds to the hormone aldosterone. When that receptor is overactive, it drives inflammation and fibrosis, a kind of internal scarring, in the heart and kidneys over time. Finerenone quiets it, and that protective effect is what the drug is built around.

This is not a brand-new idea. Older drugs, spironolactone and eplerenone, block the same receptor and have been used for years in heart failure and high blood pressure. What sets finerenone apart is how it does it. It is a nonsteroidal blocker, more selective for the target and spread more evenly between heart and kidney tissue, and it largely avoids the hormonal side effects that limit spironolactone, such as breast tenderness and enlargement in men. In its trials, that side effect was no more common than with placebo.

What does it do for the kidneys and heart?

The evidence comes from two large trials in people with type 2 diabetes and chronic kidney disease. The first, FIDELIO-DKD, focused on the kidneys and found that finerenone slowed the progression of kidney disease by about 18% compared with placebo, added on top of standard treatment.¹ The second, FIGARO-DKD, focused on the heart and found about a 13% reduction in cardiovascular events, driven mainly by fewer hospitalizations for heart failure.² A combined analysis of both confirmed benefits for both organs.⁴

The precise picture matters here. Finerenone does not reverse kidney disease; it slows its decline and reduces the protein leaking into the urine that marks the damage. The effect sizes are meaningful but moderate, in the range of a 13 to 18% reduction in risk rather than a dramatic cure. That is still valuable in a disease where few treatments have moved the needle for decades.

What about kidney disease without diabetes?

For years, finerenone's kidney evidence was confined to people with type 2 diabetes, which is why its approved kidney use is diabetic kidney disease. That began to change in 2026. The FIND-CKD trial tested finerenone in about 1,584 people who had chronic kidney disease with protein leaking into the urine but who did not have diabetes, added on top of standard blood-pressure medication. It met its main goal of slowing the yearly decline in kidney filtration, reduced a combined measure of kidney failure and major kidney decline by about 26%, and cut the urine protein by about 42%.⁵

The significance is that this extends finerenone's protection beyond diabetes, positioning it, alongside SGLT2 inhibitors and standard blood-pressure drugs, as a tool for protein-leaking kidney disease whatever its cause. One caveat belongs with it: as of 2026 this is trial evidence, and finerenone is not yet FDA-approved for kidney disease without diabetes, so using it there is currently off-label, pending a possible expansion of the approval. The direction of travel is that finerenone is becoming a broader kidney drug than its original diabetes label suggests.

The newer chapter: heart failure

For years, finerenone was a diabetes-and-kidney drug. That changed in 2024, when a trial called FINEARTS-HF tested it in people with heart failure of the kind that has a preserved or only mildly reduced pumping function, a type that has been stubbornly hard to treat. Finerenone reduced worsening heart failure events and cardiovascular death by about 16%.³ Notably, this trial enrolled people whether or not they had diabetes or kidney disease, which broadened who the drug might help.

On the strength of that result, the FDA approved finerenone for this form of heart failure in 2025, making it the first nonsteroidal drug of its class cleared for that use. So finerenone now spans two related jobs: protecting the kidneys in diabetes, and protecting the heart in a difficult form of heart failure.

Who is finerenone for, and what is the main risk?

Finerenone is for a specific group rather than the general public. The clearest cases are someone with type 2 diabetes and chronic kidney disease, shown by reduced kidney function or protein in the urine, who is already on a standard kidney-protective medicine, and, more recently, someone with heart failure whose heart pumps at a preserved or mildly reduced level. It is an add-on to good background care rather than a first move or a drug for otherwise healthy people.

The risk that defines finerenone is high potassium, called hyperkalemia. By blocking the aldosterone pathway, the drug can raise blood potassium, which at high levels can affect the heart rhythm. This is manageable but requires respect: potassium and kidney function are checked before starting, a few weeks after starting or increasing the dose, and periodically after that, and the drug is not started if potassium is already high. It is also kept away from certain other drugs that raise potassium, including the older drugs in its own family. Handled with that monitoring, it is safe for the right patient.

How does it fit with SGLT2 inhibitors and other drugs?

Modern kidney and heart protection in diabetes is built in layers. The foundation is a blood-pressure medicine that also protects the kidney, an ACE inhibitor or ARB, taken at the highest tolerated dose. On top of that sit two newer classes with their own outcome trials: SGLT2 inhibitors, and finerenone. Guidelines increasingly picture these as complementary pillars, each lowering risk through a different mechanism.

One caveat belongs here. The big finerenone trials were run before SGLT2 inhibitors were widely used, so few patients were on both, which means the benefit of stacking finerenone on top of an SGLT2 inhibitor rests more on the logic of different mechanisms and on guideline judgment than on a dedicated trial of the combination measuring hard outcomes. In practice, for a high-risk patient with diabetic kidney disease, using both is increasingly common and sensible, with careful attention to potassium. The right combination is a decision to make with your physician.

Guidance from the Clinic

"Finerenone is one of those drugs that does not make headlines but changes outcomes for a group that badly needs it. For my patients with diabetes whose kidneys are slipping despite good blood pressure and sugar control, it is a meaningful addition to the toolkit, alongside an SGLT2 inhibitor. I set expectations plainly: it slows the decline, it does not reverse it, and the numbers are steady rather than miraculous. What I never skip is the potassium check, because that is where this drug earns its caution. What excites me most is the newer heart failure data, which opens the door to helping people who did not have a good option before. It is not a longevity drug, and I would never frame it that way, but protecting the heart and kidneys is its own kind of longevity."

Related at Fishtown Medicine

• SGLT2 Inhibitors: Heart, Kidney, and Longevity - the companion pillar of cardio-renal protection
• Semaglutide (Ozempic) for Kidney Disease - the GLP-1 pillar of kidney protection, from the FLOW trial
• Metabolic Health Overview - where diabetes risk begins
• Ozempic vs Metformin - other diabetes-related drug choices
• What Is a Preventive Cardiologist? - the decision layer around heart-protective drugs
• Acarbose: The Diabetes Drug With a Longevity Signal - another metabolic drug in the mix
• Primary Aldosteronism: The Curable High Blood Pressure Doctors Miss - the aldosterone-driven hypertension that MRAs like finerenone target

Scientific References

1. Bakris GL, Agarwal R, Anker SD, et al. "Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes." New England Journal of Medicine. 2020;383(23):2219-2229.
2. Pitt B, Filippatos G, Agarwal R, et al. "Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes." New England Journal of Medicine. 2021;385(24):2252-2263.
3. Agarwal R, Filippatos G, Pitt B, et al. "Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis." European Heart Journal. 2022;43(6):474-484.
4. Solomon SD, McMurray JJV, Vaduganathan M, et al. "Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction." New England Journal of Medicine. 2024;391(16):1475-1485.
5. Heerspink HJL, Perkovic V, et al. "Finerenone in Persons with Chronic Kidney Disease without Diabetes (FIND-CKD)." New England Journal of Medicine. 2026. DOI: 10.1056/NEJMoa2604625.